Oral corticosteroids for multiple sclerosis relapse

Affiliations

¹ Department of Neurology, Institute of Experimental Neurology, Vita-Salute San Raffaele University, Hospital San Raffaele, Milan 20132, Italy. Electronic address: comi.giancarlo@hsr.it.
² Department of Neurology, Institute of Experimental Neurology, Vita-Salute San Raffaele University, Hospital San Raffaele, Milan 20132, Italy.

Comment

Giancarlo Comi et al. Lancet. 2015.

. 2015 Sep 5;386(9997):937-9.

doi: 10.1016/S0140-6736(15)00072-0.

¹ Department of Neurology, Institute of Experimental Neurology, Vita-Salute San Raffaele University, Hospital San Raffaele, Milan 20132, Italy. Electronic address: comi.giancarlo@hsr.it.
² Department of Neurology, Institute of Experimental Neurology, Vita-Salute San Raffaele University, Hospital San Raffaele, Milan 20132, Italy.

No abstract available

Comment on

Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial.
Le Page E, Veillard D, Laplaud DA, Hamonic S, Wardi R, Lebrun C, Zagnoli F, Wiertlewski S, Deburghgraeve V, Coustans M, Edan G; COPOUSEP investigators; West Network for Excellence in Neuroscience. Le Page E, et al. Lancet. 2015 Sep 5;386(9997):974-81. doi: 10.1016/S0140-6736(15)61137-0. Epub 2015 Jun 28. Lancet. 2015. PMID: 26135706 Clinical Trial.